The global idiopathic thrombocytopenic purpura therapeutics market is projected to experience substantial growth, with a ...

NEW DELHI, (IANS) – The risk-benefit of AstraZeneca’s Covid-19 vaccine is currently against further use, said experts on May ...

Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived ...

Stopped manufacturing, supply of additional Covishield doses, disclosed all side effects: Serum Institute of India after AstraZeneca recalled its vaccine ...

Viral infections like chickenpox cause a common type of purpuric rash. This is called an acute thrombocytopenic purpura. It ...

Purpose. A case of a patient who developed thrombotic thrombocytopenic purpura (TTP) after consuming a weight-loss product containing green tea is reported. Summary. A 38-year-old, 68-kg Caucasian ...

The antivaccine lobby had a field day with fuelling the “infodemic”, including other false claims such as fabricated links ...

In a significant move, pharma giant AstraZeneca has recalled its Covid-19 vaccine, made in collaboration with Oxford University, worldwide ...

The risk-benefit of AstraZeneca's Covid-19 vaccine is currently against further use, said experts on Wednesday amid a report ...

But sometimes the spleen becomes overactive and begins removing healthy cells. For example, idiopathic thrombocytopenic purpura (ITP) may develop when platelets (clotting blood cells that prevent ...

Opens in a new tab or window A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP ...

Prophylaxis with recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura (TTP) leads to ADAMTS13 activity reaching approximately 100 percent of normal levels, according to ...